



Korea's leading biotech company to develop antibody-based innovative therapeutics for the treatment of cancer and neurological diseases



www.ablbio.com

## ABL Bio, Inc.

CEO  
Sang Hoon Lee

Location  
2nd Floor, 16 Daewangpangyo-Ro 712 Beon-Gil,, Bundang-Gu, Seongnam-Si, Gyeonggi-Do, 13488, South Korea

Specialty  
Immuno-oncology Therapeutics, Multispecific Antibody, BBB-penetrating Platform Technology

Tel / Fax / E-mail  
T. 82-31-8018-9800  
F. 82-31-8018-9836  
E. Info@ablbio.com

ABL Bio founded in 2016 is a fast growing biotechnology company developing novel innovative antibody therapeutics in the field of immuno-oncology and neurodegenerative diseases. ABL Bio develops more than 20 pipelines based on an unique bispecific antibody (BsAb) platform technology. ABL001 is the most advanced BsAb asset, targeting VEGF and DLL4, which is ongoing phase 1 clinical study. ABL Bio's BsAb platform technology enables to connect two different antibodies together, ensuing synergistic activity of the two antibodies. Grabody™ T belongs to a T cell engaging bispecific antibody and Grabody™ I is a dual immune modulating bispecific antibody for cancer treatment. Grabody™ B is a bispecific antibody using blood-brain barrier (BBB)-penetrating platform for neurodegenerative disease treatment.

### Main Products



ABL001(NOV1501)

Product type	specific indication	Development Stage
ABL001(NOV1501)	a bispecific antibody therapeutics for malignant solid tumor	scheduled to conduct clinical trials of 1b/2

### R&D Pipeline

		Indication	Early Discovery	Late Discovery	Pre-Clinical	Phase I	Phase II/ III
Angiogenesis	ABL001 (Anti-VEGF/DLL4 BsAb)	Solid Cancer	[Progress bar]			[Icon]	[Icon]
Antibody-Drug Conjugate (ADC)	ABL20X	Cancer	[Progress bar]			[Icon]	[Icon]
NexMab™ (ADC)	Grabody™ T(4-1BB) (Multiple Pipelines) ABL10X	Cancer	[Progress bar]			[Icon]	TAAx4-1BB BsAb
	Grabody™ I (PD-L1) ABL50X	Cancer	[Progress bar]			[Icon]	PD-L1xLAG3 PD-L1x4-1BB BsAb
	I/O mAb ABL40X	Cancer	[Progress bar]	[Icon]			Novel I/O mAb
SC drug delivery	Grabody™ B ABL301 (α-Synuclein / IGF1R)	Parkinson's Disease	[Progress bar]			[Icon]	